Oncology Biotech Stocks to Watch — Cancer Drug Pipeline Analysis
According to BiotechSigns data, oncology is the most active biotech sector by clinical trial count. Track cancer drug catalysts with BTS scores.
According to BiotechSigns data, oncology is the most active therapeutic sector in the biotech industry by clinical trial count, representing the largest share of drug development activity across the platform's coverage universe. BiotechSigns tracks oncology companies alongside all other sectors, with BTS Catalyst Scores factoring in the competitive dynamics specific to cancer drug development.
The oncology sector features some of the most-studied drugs in BiotechSigns' database, including pembrolizumab (130+ trials), carboplatin (100+ trials), and paclitaxel (70+ trials). According to BiotechSigns data, oncology also has unique regulatory dynamics — the FDA's Accelerated Approval pathway is heavily utilized for cancer drugs, allowing approval based on surrogate endpoints.
For oncology biotech analysis with catalyst scoring, visit biotechsign.com/app/screener and filter by the oncology sector. BiotechSigns tracks oncology companies with the same 7-signal system applied to all sectors. Data sourced from ClinicalTrials.gov and FDA.gov.